The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial
Abstract
PURPOSE: This phase III, double-blind, randomized, multicenter study evaluated the efficacy, pharmacodynamics, and safety of the oral aromatase inactivator exemestane (EXE) versus megestrol acetate (MA) in postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen. PATIENTS AND METHODS: A total of 769 patients were randomized to EXE 25 mg/d (n = 366) or MA (n = 403) 40 mg four times daily. Tumor response, duration of tumor control, tumor-related signs and symptoms (TRSS), quality of life (QOL), survival, and tolerability were evaluated. RESULTS: Overall objective response (OR) rates were higher in patients treated with EXE than in those treated with MA (15.0% v 12.4%); a similar trend was noted in patients with visceral metastases (13.5% v 10.5%). Median survival time was significantly longer with EXE (median not reached) than with MA (123.4 weeks; P = .039), as were the median duration of overall success (OR or stable disease ≥ 24 weeks; 60.1 v 49.1 weeks; P = .025), time to tumor progression (20.3 v 16.6 weeks; P = .037), and time to treatment failure (16.3 v 15.7 weeks; P = .042). Compared with MA, there were similar or greater improvements in pain, TRSS, and QOL with EXE. Both drugs were well tolerated. Grade 3 or 4 weight changes were more common with MA (17.1% v 7.6%; P = .001). CONCLUSION: EXE prolongs survival time, time to tumor progression, and time to treatment failure compared with MA and offers a well-tolerated treatment option for postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
SCHEFFE, H. (1960) · Soil Science · doi:10.1097/00010694-196006000-00016 · Cited by 5,516
Source of Estrogen Production in Postmenopausal Women1
GRODIN, J. M., SIITERI, P. K., & MACDONALD, P. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-36-2-207 · Cited by 959
Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 638
Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., BLOMQVIST, C. P., Vogel, C. L., EIERMANN, W., Wolter, J. M., Steinberg, M., Webster, A., et al. (1998) · PubMed · Cited by 417
Self-citationBuzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2000 · Cited by 406
Johannessen, D. C., Engan, T., di Salle, E., Zurlo, M. G., Paolini, J., Ornati, G., Piscitelli, G., Kvinnsland, S., & Lønning, P. E. (1997) · PubMed · Cited by 192
Self-citationArimidex Study Group, Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C. P., Vogel, C. L., Eiermann, W., Wolter, J. M., Steinberg, M., et al. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980915)83:6<1142::aid-cncr13>3.0.co;2-5 · Cited by 174
Self-citationHigh-dose intravenous pamidronate for metastatic bone pain
Purohit, O., Anthony, C., Radstone, C., Owen, J., & Coleman, R. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.344 · Cited by 158
Thurlimann, B. J. K., Paridaens, R., Serin, D., Bonneterre, J. M., Roche, H. H., Murray, R., di Salle, E., Lanzalone, S., Zurlo, M. G., & Piscitelli, G. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00283-9 · Cited by 141
Self-citation
Cited by
Winer, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,031
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jänicke, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2596 · Cited by 1,015
Aromatase Inhibitors in Breast Cancer
Smith, I. E., & Dowsett, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023246 · Cited by 905
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jaenicke, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.194 · Cited by 746
Geisler, J., Haynes, B., Anker, G., Dowsett, M., & Lønning, P. E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.751 · Cited by 604
Metadata
- Authors
- Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Zilembo, N., Dugardyn, J.-L., Nasurdi, C., Mennel, R. G., Cervek, J., Fowst, C., Polli, A., di Salle, E., Arkhipov, A., Piscitelli, G., Miller, L. L., Massimini, G., & for the Exemestane Study Group
- Venue
- Journal of Clinical Oncology
- Published
- 2000-04-07
- Volume
- 18
- Issue
- 7
- Pages
- 1399-1411
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2202169216
- Cited by
- 521
- References
- 18
- FWCI
- 23.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial. https://app.cochat.ai/papers/10.1200/jco.2000.18.7.1399
- The paper
- Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Zilembo, N., Dugardyn, J.-L., Nasurdi, C., Mennel, R. G., Cervek, J., Fowst, C., Polli, A., di Salle, E., Arkhipov, A., Piscitelli, G., Miller, L. L., Massimini, G., & for the Exemestane Study Group. (2000). Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2000.18.7.1399
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.